Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma

João Pedro Ferreira, Isabel Almeida, António Marinho, Conceição Cerveira, Carlos Vasconcelos, João Pedro Ferreira, Isabel Almeida, António Marinho, Conceição Cerveira, Carlos Vasconcelos

Abstract

Introduction. The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, particularly in myositis, scleroderma, and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies remains controversial, and studies are lacking for clarifying the association of anti-Ro52 with interstitial lung disease (ILD) in connective tissue diseases (CTD). Objectives. To determine if anti-Ro52 antibodies are associated with ILD in CTD other than scleroderma. Methods. Single-center, retrospective study based on immunoblotting panel analysis and patients clinical records. Results. In our connective tissue disease cohort, 162 patients had immunoblotting panels with anti-Ro52 reactivity analysis, 41 (25,3%) had inclusion criteria. Among the 41 selected sera, 85.4% (n = 35) had anti-Ro52 reactivity. The prevalence of ILD in the positive anti-Ro52 antibodies was 71.4% (n = 25), and 16.7% (n = 1) in the negative anti-Ro52 group (P = 0.018). Overall sensitivity (96.2%), specificity (83.3%), positive (71.4%) and negative (83.3%) predictive values of anti-Ro52 antibodies to determine ILD in CTD is detailed in this study. Conclusion. Ro52 autoantibodies are associated with ILD in CTD excluding scleroderma. We suggest that the presence of anti-Ro52 reactivity in CTD should increase the clinician curiosity for the search of ILD.

References

    1. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmunity Reviews. 2009;8(7):632–637.
    1. Ben-Chetrit E, Chan EKL, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. Journal of Experimental Medicine. 1988;167(5):1560–1571.
    1. Chan EKL, Hamel JC, Buyon JP, Tan EM. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. Journal of Clinical Investigation. 1991;87(1):68–76.
    1. Defendenti C, Atzeni F, Spina MF, et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmunity Reviews. 2011;10(3):150–154.
    1. Frank MB, Itoh K, Fujisaku A, Pontarotti P, Mattei MG, Neas BR. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome II, and its polymorphisms. American Journal of Human Genetics. 1993;52(1):183–191.
    1. Rhodes DA, Ihrke G, Reinicke AT, et al. The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-γ inducible tripartite motif protein associated with membrane proximal structures. Immunology. 2002;106(2):246–256.
    1. Rutjes SA, Vree Egberts WTM, Jongen P, Van Den Hoogen F, Pruijn GJM, Van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clinical and Experimental Immunology. 1997;109(1):32–40.
    1. Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics. 2007;26(6):831–838.
    1. Hervier B, Rimbert M, Colonna F, Hamidou MA, Audrain M. Clinical significance of anti-Ro/SSA-52 kDa antibodies—a retrospective monocentric study. Rheumatology. 2009;48(8):964–967.
    1. Ghillani P, André C, Toly C, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmunity Reviews. 2011;10(9):509–513.
    1. Rhodes DA, Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Molecular Immunology. 2007;44(9):2406–2414.
    1. Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Annals of the Rheumatic Diseases. 2002;61(10):929–933.
    1. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39(3):249–253.
    1. Sibilia J, Chatelus E, Meyer A, Gottenberg JE, Sordet C, Goetz J. How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies. Presse Medicale. 2010;39(10):1010–1025.
    1. Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. Journal of Experimental Medicine. 2009;206(8):1661–1671.
    1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism. 1997;40(9):p. 1725.
    1. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Annals of the Rheumatic Diseases. 2002;61(6):554–558.
    1. Hervier B, Rimbert M, Colonna F, Hamidou MA, Audrain M. Clinical significance of anti-Ro/SSA-52 kDa antibodies—a retrospective monocentric study. Rheumatology. 2009;48(8):964–967.
    1. Langguth DM, Morris S, Clifford L, et al. Specific testing for "isolated" anti-52 kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value. Journal of Clinical Pathology. 2007;60(6):670–673.
    1. Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis and Rheumatism. 2007;56(8):2729–2739.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit